New Zealand biotech news
BioEnceptionz revamp their efforts to raise funds to build biogas digesters for Piu Village in Samoa.
US-based ArborGen LLC, which is one-third owned by NZ firm Rubicon Limited, has entered into agreements to acquire the commercial tree improvement operations of International Paper, Mead Westvaco and Rubicon's Horizon2.
Genesis Research and Development announced better-than-budget results in their half-year financial report and expect milestone achievements over the coming months.
Gull New Zealand has launched the first commercially available biofuel for New Zealand motorists.
Soil & Health Association claim that food safety trials of GE corn were flawed.
Genesis Research and Development's subsidiary reported that they have produced an expanded polyurethane foam from natual lignin extracted from shrubby willow.
LIC sells Animal Breeding Services
LIC have sold their subsidiary ABS in a move to reduce investment in In-Vitro Production technology.
GE-Free New Zealand appeal to the High Court, claiming breaches in law relating to GE field trials.
AusBiotech have created the BioNet Asia Pacific Initiative
BIO-Europe features presentations, exhibitions and networking opportunities for international biotechnology, pharmaceutical and financial companies. This year's conference will take place in Hamburg, Germany from Novemeber 12-14.
Pharmaceutical market predicted to double by 2020
In their recently released report Pharma 2020: The vision - Which path will you take?, PwC predict that the worldwide pharmaceutical market will more than double to $1.3 trillion.
Human stem cells injected into monkeys with Parkinson's
In the search for a Parkinson's cure, US researchers injected stem cells into monkeys and observed their damaged brain cells stopped deteriorating for a period of a few months.